A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

The primary purpose of this study is to evaluate the safety and tolerability of VRG50635 in participants with ALS.

PHASE1

Verge Genomics